Mendus: Partnering with Global TFR Pioneers for Phase IIa Leukemia Trial - Redeye

Mendus has partnered with Australia’s SAHMRI for its upcoming Phase IIa VITAL-TFR2 trial, targeting Chronic Myeloid Leukemia patients attempting a second treatment-free remission. By deploying the vididencel immunotherapy against a group facing a steep 70% standard relapse rate, this collaboration offers a highly efficient way to prove clinical efficacy without a massive placebo-controlled study.

Länk till analysen i sin helhet: https://www.redeye.se/research/1174977/mendus-partnering-with-global-tfr-pioneers-for-phase-iia-leukemia-trial?utm_source=finwire&utm_medium=RSS